NS 49

Drug Profile

NS 49

Alternative Names: ABT 232; PNO 49B

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Shinyaku
  • Developer Abbott Laboratories; Nippon Shinyaku; Sanofi-Synthelabo
  • Class Anilides; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stress incontinence; Urinary incontinence

Most Recent Events

  • 09 Mar 2001 Discontinued-II for Stress incontinence in USA (Unknown route)
  • 09 Mar 2001 Discontinued-II for Urinary incontinence in European Union (Unknown route)
  • 09 Mar 2001 Discontinued-II for Urinary incontinence in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top